Substance / Medication

Tecovirimat

Overview

Active Ingredient
tecovirimat
RxNorm CUI
2055104
Labeler: SIGA Technologies, Inc.Updated: 2025-12-31T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

TPOXX Capsules: None. TPOXX Injection: 5.2 8.6 [see Warnings and Precautions () and Use in Specific Populations ()] The excipient hydroxypropyl-β-cyclodextrin is eliminated through glomerular filtration. Therefore, TPOXX Injection is contraindicated in patients with severe renal impairment (defined

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effectiveness of Tecovirimat in Mpox Cases: A Systematic Review of Current Evidence.
Shabil Muhammed, Khatib Mahalaqua Nazli, Ballal Suhas et al. · J Med Virol · 2024
PMID: 39707867Meta-Analysis
Oral Tecovirimat for the Treatment of Smallpox.
Grosenbach Douglas W, Honeychurch Kady, Rose Eric A et al. · N Engl J Med · 2018
PMID: 29972742RCTFull text (PMC)
Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.
[object Object], Ali Rosine, Alonga Jules et al. · N Engl J Med · 2025
PMID: 40239067TrialFull text (PMC)
Efficacy and viral dynamics of tecovirimat in patients with MPOX: A multicenter open-label, double-arm trial in Japan.
Akiyama Yutaro, Morioka Shinichiro, Tsuzuki Shinya et al. · J Infect Chemother · 2024
PMID: 38042298Trial
Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox.
Mazzotta Valentina, Cozzi-Lepri Alessandro, Lanini Simone et al. · J Med Virol · 2023
PMID: 37306318Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tecovirimat (substance)
SNOMED CT
772991002
UMLS CUI
C2713595
RxNorm CUI
2055104
Labeler
SIGA Technologies, Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.